Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis

7 Nov 2023

Abstract excerpt

Emerging evidence shows that KRAS-mutant colorectal cancer (CRC) depends on glutamine (Gln) for survival and progression, indicating that targeting Gln metabolism may be a promising therapeutic strategy for KRAS-mutant CRC. However, the precise mechanism by which Gln metabolism reprogramming promotes and coordinates KRAS-mutant CRC progression remains to be fully investigated. Here, we discovered that solute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37937641
DOI: 10.1172/jci.insight.167874

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosisPMID 37937641Read ↗

The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.Semantic proximity Read ↗

SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.Semantic proximity Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.Semantic proximity Read ↗

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic OpportunitiesSemantic proximity Read ↗

Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.Semantic proximity Read ↗

Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.Semantic proximity Read ↗

FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.Semantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapySemantic proximity Read ↗

EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.